PLA2G4A

Across TCGA pan-cancer cohorts, PLA2G4A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PLA2G4A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PLA2G4A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PLA2G4A is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where PLA2G4A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLA2G4A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.865	<.001	11	view →
COAD	Male	III,IV	−0.606	<.001	9	view →
LUAD	All	II,III,IV	+0.637	<.001	8	view →
PDAC	Female	All	+0.617	<.001	8	view →
HNSC	Female	IV	−0.250	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PLA2G4A–CCRCC

Open the CCRCC breakdown →